Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 19, 2013 Filed Apr 23, 2013 20:31 UTC |
Silva Paul MSVP & Corp Controller
|
SaleCommon Stock | 22,549 | $81.50 | $1,837,743.50 |
DisclosureSEC source: 0001209191-13-022281 · doc4.xml · nonDerivative · entry 10 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 19, 2013 Filed Apr 23, 2013 20:31 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionCommon Stock | 2,250 | $48.74 | $109,665.00 |
DisclosureSEC source: 0001209191-13-022281 · doc4.xml · nonDerivative · entry 9 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2013 Filed Apr 23, 2013 20:31 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionCommon Stock | 3,375 | $37.86 | $127,777.50 |
DisclosureSEC source: 0001209191-13-022281 · doc4.xml · nonDerivative · entry 8 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2013 Filed Apr 23, 2013 20:31 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionCommon Stock | 4,500 | $51.75 | $232,875.00 |
DisclosureSEC source: 0001209191-13-022281 · doc4.xml · nonDerivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2013 Filed Apr 23, 2013 20:31 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionCommon Stock | 2,813 | $38.80 | $109,144.40 |
DisclosureSEC source: 0001209191-13-022281 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2013 Filed Apr 23, 2013 20:31 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionCommon Stock | 1,875 | $33.82 | $63,412.50 |
DisclosureSEC source: 0001209191-13-022281 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2013 Filed Apr 23, 2013 20:31 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionCommon Stock | 2,813 | $39.05 | $109,847.65 |
DisclosureSEC source: 0001209191-13-022281 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2013 Filed Apr 23, 2013 20:31 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionCommon Stock | 1,875 | $33.28 | $62,400.00 |
DisclosureSEC source: 0001209191-13-022281 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2013 Filed Apr 23, 2013 20:31 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionCommon Stock | 2,813 | $33.55 | $94,376.15 |
DisclosureSEC source: 0001209191-13-022281 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2013 Filed Apr 23, 2013 20:31 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionCommon Stock | 235 | $32.16 | $7,557.60 |
DisclosureSEC source: 0001209191-13-022281 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 21:17 UTC |
BOGER JOSHUA SDirector
|
GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-013259 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,895 F1 · kind: Gifts to charitable organizations. Read SEC document |
| February 06, 2013 Filed Feb 7, 2013 22:29 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 33,345 | $45.83 | $1,528,201.35 |
DisclosureSEC source: 0001209191-13-007122 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,371 F2 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, established to sell a portion of shares upon vesting to cover tax laibilities. F3 · price: Open market sales reported on this line occurred at a weighted average price of $45.83 (range $45.57 to $46.08). F4 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:29 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantEmployee Stock Option (right to buy) · Derivative | 177,000 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007122 · doc4.xml · derivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,000 Underlying: Common Stock · 177,000 shares Expires 2023-02-04 F5 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:29 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantCommon Stock | 39,334 | $0.01 | $393.34 |
DisclosureSEC source: 0001209191-13-007122 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,716 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:31 UTC |
Arbuckle Stuart AEVP\Chief Commercial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 90,625 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007124 · doc4.xml · derivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,625 Underlying: Common Stock · 90,625 shares Expires 2023-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:31 UTC |
Arbuckle Stuart AEVP\Chief Commercial Officer
|
GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0001209191-13-007124 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,751 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:31 UTC |
Horton Kenneth LEVP & Chief Legal Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 90,625 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007125 · doc4.xml · derivative · entry 2 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,625 Underlying: Common Stock · 90,625 shares Expires 2023-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:31 UTC |
Horton Kenneth LEVP & Chief Legal Officer
|
GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0001209191-13-007125 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,751 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:32 UTC |
Kelly LisaSVP, Human Resources
|
GrantEmployee Stock Option (right to buy) · Derivative | 45,750 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007127 · doc4.xml · derivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2023-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:32 UTC |
Kelly LisaSVP, Human Resources
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0001209191-13-007127 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,382 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:32 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
GrantEmployee Stock Option (right to buy) · Derivative | 54,375 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007128 · doc4.xml · derivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,375 Underlying: Common Stock · 54,375 shares Expires 2023-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:32 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0001209191-13-007128 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,400 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:33 UTC |
Pace Megan ESVP, Corp. Communications
|
GrantEmployee Stock Option (right to buy) · Derivative | 45,750 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007129 · doc4.xml · derivative · entry 2 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2023-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:33 UTC |
Pace Megan ESVP, Corp. Communications
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0001209191-13-007129 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,915 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:34 UTC |
Silva Paul MSVP & Corp Controller
|
GrantEmployee Stock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007131 · doc4.xml · derivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2023-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:34 UTC |
Silva Paul MSVP & Corp Controller
|
GrantCommon Stock | 5,625 | $0.01 | $56.25 |
DisclosureSEC source: 0001209191-13-007131 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:34 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
GrantEmployee Stock Option (right to buy) · Derivative | 45,750 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007130 · doc4.xml · derivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2023-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:34 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0001209191-13-007130 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,987 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:35 UTC |
SMITH IAN FEVP & CFO
|
GrantEmployee Stock Option (right to buy) · Derivative | 54,375 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007133 · doc4.xml · derivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,375 Underlying: Common Stock · 54,375 shares Expires 2023-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:35 UTC |
SMITH IAN FEVP & CFO
|
GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0001209191-13-007133 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,210 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:36 UTC |
Stamoulis ChristianaSVP, Corp Strategy & Bus Devlp
|
GrantEmployee Stock Option (right to buy) · Derivative | 45,750 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007136 · doc4.xml · derivative · entry 3 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2023-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:36 UTC |
Stamoulis ChristianaSVP, Corp Strategy & Bus Devlp
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0001209191-13-007136 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,712 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| January 02, 2013 Filed Jan 3, 2013 21:18 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,951 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0001209191-13-001087 · doc4.xml · derivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,951 shares Expires 2013-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| January 02, 2013 Filed Jan 3, 2013 21:18 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 2,951 | $43.09 | $127,158.59 |
DisclosureSEC source: 0001209191-13-001087 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,895 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $43.09 (range $42.73 to $43.54). F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2013 Filed Jan 3, 2013 21:18 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionCommon Stock | 2,951 | $15.60 | $46,035.60 |
DisclosureSEC source: 0001209191-13-001087 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 635,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 26, 2012 Filed Dec 27, 2012 21:20 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0001209191-12-059483 · doc4.xml · derivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,951 Underlying: Common Stock · 4,000 shares Expires 2013-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| December 26, 2012 Filed Dec 27, 2012 21:20 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 4,000 | $41.86 | $167,440.00 |
DisclosureSEC source: 0001209191-12-059483 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,895 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $41.86 (range $41.67 to $42.08). F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 26, 2012 Filed Dec 27, 2012 21:20 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionCommon Stock | 4,000 | $15.60 | $62,400.00 |
DisclosureSEC source: 0001209191-12-059483 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2012 Filed Dec 20, 2012 21:46 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0001209191-12-058837 · doc4.xml · derivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,951 Underlying: Common Stock · 4,000 shares Expires 2013-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| December 19, 2012 Filed Dec 20, 2012 21:46 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 300 | $44.11 | $13,233.00 |
DisclosureSEC source: 0001209191-12-058837 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,895 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $44.11 (range $44.04 to $44.23). Read SEC document |
| December 19, 2012 Filed Dec 20, 2012 21:46 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 3,700 | $43.39 | $160,543.00 |
DisclosureSEC source: 0001209191-12-058837 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633,195 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $43.39 (range $43.00 to $43.98). F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 19, 2012 Filed Dec 20, 2012 21:46 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionCommon Stock | 4,000 | $15.60 | $62,400.00 |
DisclosureSEC source: 0001209191-12-058837 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2012 Filed Dec 13, 2012 21:22 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0001209191-12-057402 · doc4.xml · derivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,951 Underlying: Common Stock · 4,000 shares Expires 2013-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| December 12, 2012 Filed Dec 13, 2012 21:22 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 4,000 | $42.07 | $168,280.00 |
DisclosureSEC source: 0001209191-12-057402 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,895 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $42.07 (range $41.85 to $42.35). F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 12, 2012 Filed Dec 13, 2012 21:22 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionCommon Stock | 4,000 | $15.60 | $62,400.00 |
DisclosureSEC source: 0001209191-12-057402 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2012 Filed Dec 6, 2012 21:20 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0001209191-12-056111 · doc4.xml · derivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,951 Underlying: Common Stock · 4,000 shares Expires 2013-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| December 05, 2012 Filed Dec 6, 2012 21:20 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 4,000 | $39.35 | $157,400.00 |
DisclosureSEC source: 0001209191-12-056111 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,895 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $39.35 (range $39.20 to $39.50). F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 05, 2012 Filed Dec 6, 2012 21:20 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionCommon Stock | 4,000 | $15.60 | $62,400.00 |
DisclosureSEC source: 0001209191-12-056111 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2012 Filed Nov 30, 2012 17:31 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0001209191-12-055056 · doc4.xml · derivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,951 Underlying: Common Stock · 4,000 shares Expires 2013-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| November 28, 2012 Filed Nov 30, 2012 17:31 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 4,000 | $39.34 | $157,360.00 |
DisclosureSEC source: 0001209191-12-055056 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,895 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $39.34 (range $38.69 to $39.59). F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.